Cardiovascular disease after renal transplantation

被引:61
作者
Dimény, EM [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
关键词
cardiovascular disease; renal transplantation; hyperlipidemia; metabolic risk factors; hyperhomocysteinemia;
D O I
10.1046/j.1523-1755.61.s80.14.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease after renal transplantation. Cardiovascular disease is a major hazard limiting the life expectancy of renal transplant recipients and the most frequent cause of late allograft loss. Patients with renal disease have usually been exposed for both traditional, and for them unique, risk factors over a prolonged period of time and may carry the burden of advanced atherosclerotic disease already at the time of transplantation. The observed survival benefit of transplantation is probably from elimination of the numerous uremia-related risk factors. However. immunosuppressive therapy and the chronic inflammatory state. together with genetic susceptibility and not infrequently impaired renal function, may bring about new potentially atherogenic conditions. Metabolic risk factors may jeopardize both patient and graft survival. Several observational studies provide evidence for the negative impact of preexisting metabolic abnormalities on long-term outcomes. Identification of modifiable cardiovascular risk factors may enable risk reduction also in renal transplant recipients, Results of ongoing intervention trials are awaited. The observed improvement of patient survival after renal transplantation during the past decade may reflect the increasing awareness and more optimal care of patients throughout the course of renal disease.
引用
收藏
页码:S78 / S84
页数:7
相关论文
共 67 条
[1]   Cardiovascular morbidity and risk factors in renal transplant patients [J].
Aakhus, S ;
Dahl, K ;
Wideroe, TE .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (03) :648-654
[2]   Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension [J].
Abdi, R ;
Huong, TTB ;
Zee, R ;
Brenner, BM ;
Milford, EL .
TRANSPLANTATION, 2001, 72 (04) :726-729
[3]   Cardiovascular risk factors and diseases after renal transplantation [J].
Aker S. ;
Ivens K. ;
Grabensee B. ;
Heering P. .
International Urology and Nephrology, 1998, 30 (6) :777-788
[4]   Patient survival after renal transplantation; more than 25 years follow-up [J].
Arend, SM ;
Mallat, MJK ;
Westendorp, RJW ;
vanderwoude, FJ ;
vanEs, LA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1672-1679
[5]   Serum total homocysteine concentration before and after renal transplantation [J].
Arnadottir, M ;
Hultberg, B ;
Wahlberg, J ;
Fellström, B ;
Dimény, E .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1380-1384
[6]   Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients [J].
Arnadottir, M ;
Hultberg, B ;
Vladov, V ;
NilssonEhle, P ;
Thysell, H .
TRANSPLANTATION, 1996, 61 (03) :509-512
[7]   Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease [J].
Becker, BN ;
Brazy, PC ;
Becker, YT ;
Odorico, JS ;
Pintar, TJ ;
Collins, BH ;
Pirsch, JD ;
Leverson, GE ;
Heisey, DM ;
Sollinger, HW .
KIDNEY INTERNATIONAL, 2000, 57 (05) :2129-2135
[8]  
Bostom AG, 2000, J AM SOC NEPHROL, V11, P149, DOI 10.1681/ASN.V111149
[9]   Chronic renal transplantation:: a model for the hyperhomocysteinemia of renal insufficiency [J].
Bostom, AG ;
Kronenberg, F ;
Gohh, RY ;
Schwenger, V ;
Kuen, E ;
König, P ;
Kraatz, G ;
Lhotta, K ;
Mann, JFE ;
Müller, GA ;
Neyer, U ;
Riegel, W ;
Riegler, P ;
Ritz, E ;
Selhub, J .
ATHEROSCLEROSIS, 2001, 156 (01) :227-230
[10]   Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin) [J].
Brattström, C ;
Wilczek, H ;
Tydén, G ;
Böttiger, Y ;
Säwe, J ;
Groth, CG .
TRANSPLANTATION, 1998, 65 (09) :1272-1274